Company intelligence / Profile preview

Seneca Biopharma

Germantown, Maryland, United Statessenecabio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Seneca Biopharma was a clinical-stage biopharmaceutical company developing novel treatments for diseases of unmet medical need. Its legacy included a technology platform enabling the generation and commercial-scale production of regionally specific neural stem cell lines, with applications in therapeutic indications or drug screening. The company shifted focus from neurological disorders to acquiring new assets/technologies before merging with Leading BioSciences in late 2020 to form Palisade Bio. No recent independent clinical results are available post-merger.

Therapeutic areas: ImmunologyNeurology
Modalities: Cell therapyMonoclonal antibodySmall molecule
Industry: Biotech

Drug pipeline

2 assets

NSI-566

1 more asset in the full pipeline.

Request access →

Partnerships

QYuns Therapeutics

Beyond the preview

Go deeper on Seneca Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Seneca Biopharma.

Explore the full profile